GSA Capital Partners LLP Increases Stock Holdings in NewAmsterdam Pharma (NASDAQ:NAMS)

GSA Capital Partners LLP increased its holdings in NewAmsterdam Pharma (NASDAQ:NAMS) by 79.9% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 66,402 shares of the company’s stock after buying an additional 29,496 shares during the period. GSA Capital Partners LLP’s holdings in NewAmsterdam Pharma were worth $1,102,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in NAMS. StemPoint Capital LP acquired a new position in NewAmsterdam Pharma during the first quarter worth about $1,900,000. Affinity Asset Advisors LLC raised its position in shares of NewAmsterdam Pharma by 129.0% during the 1st quarter. Affinity Asset Advisors LLC now owns 286,200 shares of the company’s stock worth $6,769,000 after purchasing an additional 161,200 shares during the last quarter. Baker BROS. Advisors LP purchased a new stake in NewAmsterdam Pharma in the 1st quarter valued at approximately $2,290,000. Janus Henderson Group PLC acquired a new stake in NewAmsterdam Pharma during the 1st quarter valued at $15,018,000. Finally, Artal Group S.A. purchased a new position in NewAmsterdam Pharma during the first quarter worth $18,920,000. 89.89% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CAO Louise Frederika Kooij sold 45,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $15.72, for a total value of $707,400.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 19.50% of the company’s stock.

NewAmsterdam Pharma Stock Performance

NewAmsterdam Pharma stock opened at $24.97 on Friday. NewAmsterdam Pharma has a 1 year low of $8.90 and a 1 year high of $26.35. The firm has a 50 day moving average price of $18.18 and a 200 day moving average price of $18.56.

Analysts Set New Price Targets

NAMS has been the subject of several analyst reports. Royal Bank of Canada reissued an “outperform” rating and issued a $31.00 target price on shares of NewAmsterdam Pharma in a research note on Thursday, September 5th. Piper Sandler restated an “overweight” rating and set a $37.00 target price on shares of NewAmsterdam Pharma in a research report on Monday, September 23rd. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $36.00 price target on shares of NewAmsterdam Pharma in a report on Thursday, November 7th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $33.80.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.